

# Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P4B8BC889C35EN.html>

Date: March 2022

Pages: 124

Price: US\$ 2,000.00 (Single User License)

ID: P4B8BC889C35EN

## Abstracts

Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 5, 3, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 8, 1 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Primary Immune Deficiency (PID) - Overview

Primary Immune Deficiency (PID) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Primary Immune Deficiency (PID) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development

ADMA Biologics Inc

Biotest AG

Collectis SA

Collective BioTherapy Inc

Chengdu Rongsheng Pharmaceutical Co Ltd

Clinigen Group Plc

CSL Ltd

EmendoBio Inc

Evolve Biologics Inc

Genespire Srl

Graphite Bio Inc

Grifols SA

Grifols Therapeutics Inc

Jasper Therapeutics Inc

Kedrion SpA

Lactiga Inc

Liminal BioSciences Inc

Microgen

Mustang Bio Inc

Noga Therapeutics Ltd

Novartis AG

Octapharma AG

Orchard Therapeutics Plc  
Pfizer Inc  
Smart Immune SAS  
Sumitomo Dainippon Pharma Co Ltd  
Taiga Biotechnologies Inc  
Takeda Pharmaceutical Co Ltd  
X4 Pharmaceuticals Inc  
Primary Immune Deficiency (PID) - Drug Profiles  
aldesleukin - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
BioGam - Drug Profile  
Product Description  
Mechanism Of Action  
Biologic 1 for Genetic Disorders and Infectious Disease - Drug Profile  
Product Description  
Mechanism Of Action  
Biologic for Genetic Disorders and Infectious Disease - Drug Profile  
Product Description  
Mechanism Of Action  
BT-595 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Cellular Immunotherapy for Severe Combined Immune Deficiency and Graft Versus  
Host Disease - Drug Profile  
Product Description  
Mechanism Of Action  
Cuvitru - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
EMD-102 - Drug Profile  
Product Description  
Mechanism Of Action  
Gene Therapies for Primary Immune Deficiency - Drug Profile  
Product Description  
Mechanism Of Action

Gene Therapy for Primary Immune Deficiency - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for X-Linked SCID - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy for X-Linked SCID - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency  
Related SCID - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency  
Related SCID - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate Adenosine Deaminase for Severe Combined Immune  
Deficiency - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate Artemis for Severe Combined Immune Deficiency - Drug  
Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate Artemis for Severe Combined Immunodeficiency - Drug  
Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate IL-2 Gamma Receptor for X-Linked SCID - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate IL2RG for X-Linked SCID - Drug Profile

Product Description

Mechanism Of Action

GENE-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GPH-201 - Drug Profile

Product Description

Mechanism Of Action

History of Events

hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events



immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

IVIG-PEG - Drug Profile

Product Description

Mechanism Of Action

History of Events

JSP-191 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LCTG-001 - Drug Profile

Product Description

Mechanism Of Action

leniolisib - Drug Profile

Product Description

Mechanism Of Action

History of Events

mavorixafor - Drug Profile

Product Description

Mechanism Of Action

History of Events

MB-107 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MB-109 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Octanorm - Drug Profile

Product Description

Mechanism Of Action

History of Events

ReclG - Drug Profile

Product Description  
Mechanism Of Action  
Rethymic - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
simoladagene autotemcel - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
sirolimus - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
SMART-101 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
TAK-880 - Drug Profile  
Product Description  
Mechanism Of Action  
TAK-881 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
TalX-02 - Drug Profile  
Product Description  
Mechanism Of Action  
TalX-03 - Drug Profile  
Product Description  
Mechanism Of Action  
TBX-1400 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events

## X-4P003 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Primary Immune Deficiency (PID) - Dormant Projects

Primary Immune Deficiency (PID) - Discontinued Products

Primary Immune Deficiency (PID) - Product Development Milestones

Featured News & Press Releases

Dec 02, 2021: X4 Pharmaceuticals to host virtual seminar “Understanding Primary Immunodeficiencies” to highlight broadening market opportunities for mavorixafor

Oct 04, 2021: X4 Pharmaceuticals completes enrollment in phase 3 mavorixafor trial in patients with WHIM Syndrome

Aug 03, 2021: X4 Pharmaceuticals announces key enrollment milestone achievements in ongoing mavorixafor clinical trials and reports second quarter financial results

Jul 13, 2021: First patient treated in KIDCARES10, Kedrion Biopharma pediatric primary immunodeficiency study

May 17, 2021: Evolve Biologics confirms selection of DPR Construction as general contractor for first manufacturing facility in Texas, demonstrating further progress toward commercialization of its innovative PlasmaCap EBA technology

Apr 01, 2021: First patient enrolled in KIDCARES10, Kedrion Biopharma pediatric Primary immunodeficiency study

Mar 10, 2021: Evolve Biologics provides business update on progress toward commercialization of innovative PlasmaCap EBA technology

Feb 09, 2021: Evolve Biologics completes phase III adult and pediatric trials for PlasmaCap IG (Intravenous Immunoglobulin)

Jan 11, 2021: CARES10 clinical trial: Last patient treated in the USA

Jan 04, 2021: Kedrion Biopharma phase III trial, CARES10, achieves important milestone: last patient treated

Dec 10, 2020: X4 Pharmaceuticals receives rare pediatric disease designation from FDA for Mavorixafor for the treatment of WHIM syndrome

Oct 08, 2020: X4 Pharmaceuticals announces fast track designation granted by the FDA to Mavorixafor for the treatment of WHIM Syndrome

Sep 15, 2020: European Medicines Agency approves label update for HYQVIA (human normal immunoglobulin 10% and recombinant human hyaluronidase), expanding its use to a broader group of patients with secondary immunodeficiencies

Sep 09, 2020: Heyu Medicine's CXCR4 antagonist Mavorixafor obtains clinical trial approval in China

Sep 02, 2020: X4 Pharmaceuticals announces publication of mavorixafor phase 2 clinical data for treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the

American Society of Hematology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Primary Immune Deficiency (PID), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Biotest AG, 2022

Primary Immune Deficiency (PID) - Pipeline by Cellectis SA, 2022

Primary Immune Deficiency (PID) - Pipeline by Collective BioTherapy Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2022

Primary Immune Deficiency (PID) - Pipeline by Clinigen Group Plc, 2022

Primary Immune Deficiency (PID) - Pipeline by CSL Ltd, 2022

Primary Immune Deficiency (PID) - Pipeline by EmendoBio Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Evolve Biologics Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Genespire Srl, 2022

Primary Immune Deficiency (PID) - Pipeline by Graphite Bio Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Grifols SA, 2022

Primary Immune Deficiency (PID) - Pipeline by Grifols Therapeutics Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Jasper Therapeutics Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Kedrion SpA, 2022

Primary Immune Deficiency (PID) - Pipeline by Lactiga Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Liminal BioSciences Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Microgen, 2022

Primary Immune Deficiency (PID) - Pipeline by Mustang Bio Inc, 2022

Primary Immune Deficiency (PID) - Pipeline by Noga Therapeutics Ltd, 2022

Primary Immune Deficiency (PID) - Pipeline by Novartis AG, 2022

Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, 2022

Primary Immune Deficiency (PID) - Pipeline by Orchard Therapeutics Plc, 2022  
Primary Immune Deficiency (PID) - Pipeline by Pfizer Inc, 2022  
Primary Immune Deficiency (PID) - Pipeline by Smart Immune SAS, 2022  
Primary Immune Deficiency (PID) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022  
Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, 2022  
Primary Immune Deficiency (PID) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022  
Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, 2022  
Primary Immune Deficiency (PID) - Dormant Projects, 2022  
Primary Immune Deficiency (PID) - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Primary Immune Deficiency (PID), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P4B8BC889C35EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P4B8BC889C35EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



